Noxopharm Limited
NOXOF · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $2,400 | $6,010 | $5,429 | $5,608 |
| % Growth | -60.1% | 10.7% | -3.2% | – |
| Cost of Goods Sold | $2,935 | $155 | $262 | $262 |
| Gross Profit | -$535 | $5,856 | $5,167 | $5,347 |
| % Margin | -22.3% | 97.4% | 95.2% | 95.3% |
| R&D Expenses | $2,935 | $10,647 | $7,777 | $6,969 |
| G&A Expenses | $1,041 | $4,884 | $6,479 | $6,363 |
| SG&A Expenses | $4,065 | $5,076 | $6,583 | $7,379 |
| Sales & Mktg Exp. | $58 | $192 | $104 | $1,016 |
| Other Operating Expenses | $0 | $1,557 | -$3,429 | $0 |
| Operating Expenses | $7,000 | $16,441 | $14,946 | $14,348 |
| Operating Income | -$7,535 | -$16,595 | -$15,208 | -$14,610 |
| % Margin | -313.9% | -276.1% | -280.1% | -260.5% |
| Other Income/Exp. Net | $3,957 | $6,081 | -$1,372 | $18,587 |
| Pre-Tax Income | -$3,578 | -$21,041 | -$24,034 | -$8,306 |
| Tax Expense | $0 | -$5,985 | -$5,368 | $1,041 |
| Net Income | -$3,578 | -$15,056 | -$18,667 | -$9,347 |
| % Margin | -149.1% | -250.5% | -343.9% | -166.7% |
| EPS | -0.012 | -0.052 | -0.064 | -0.035 |
| % Growth | 76.3% | 19.7% | -81.1% | – |
| EPS Diluted | -0.012 | -0.052 | -0.064 | -0.035 |
| Weighted Avg Shares Out | 292,258 | 292,238 | 291,222 | 263,851 |
| Weighted Avg Shares Out Dil | 292,238 | 292,238 | 291,222 | 263,851 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $83 | $47 | $139 |
| Interest Expense | $31 | $41 | $77 | $2,199 |
| Depreciation & Amortization | $2 | $155 | $262 | $262 |
| EBITDA | -$4,600 | -$14,801 | -$14,946 | -$14,348 |
| % Margin | -191.6% | -246.3% | -275.3% | -255.8% |